Physiological Effect: Increased Platelet Production

Drugs with Physiological Effect: Increased Platelet Production

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	PROMACTA KIT	eltrombopag olamine	FOR SUSPENSION;ORAL	207027-001	Aug 24, 2015	AB	RX	Yes	Yes					Y
Novartis	PROMACTA KIT	eltrombopag olamine	FOR SUSPENSION;ORAL	207027-002	Sep 27, 2018	AB	RX	Yes	No					Y
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-004	Oct 20, 2011	AB	RX	Yes	No					Y

Thrombopoietin Receptor Agonists and Emerging Platelet Production Therapies: Patent Landscape and Market Dynamics

Last updated: February 19, 2026

This report analyzes the patent landscape and market dynamics for drugs that increase platelet production, focusing on thrombopoietin receptor agonists (TPO-RAs) and novel therapeutic approaches. Key patent filings and litigation events are detailed, alongside an assessment of market exclusivity and the competitive environment.

What are the key therapeutic targets for increasing platelet production?

The primary therapeutic target for increasing platelet production is the thrombopoietin (TPO) receptor. TPO is the main hormone regulating megakaryopoiesis, the process of platelet production. TPO-RAs mimic the action of endogenous TPO, binding to its receptor on megakaryocyte progenitor cells and stimulating their proliferation and differentiation, thereby increasing platelet counts.

Beyond TPO-RAs, research is exploring other pathways, including:

• Actinomycin D derivatives: Investigated for their ability to stimulate megakaryopoiesis.
• Small molecule activators of other signaling pathways: Targeting downstream signaling cascades activated by TPO or alternative pathways involved in platelet production.
• Gene therapy approaches: Aiming to enhance endogenous TPO production or expression of TPO receptors.

What is the current patent landscape for TPO-RAs?

The patent landscape for TPO-RAs is characterized by a concentration of foundational patents held by early developers, followed by a wave of subsequent patents covering second-generation molecules, manufacturing processes, formulations, and new indications.

Key TPO-RA Molecules and Their Patent Status

Drug Name	Manufacturer(s)	Primary Indication(s)	Original Patent Expiration (Approximate)	Current Patent Exclusivity Status
Eltrombopag	GlaxoSmithKline (GSK) / Shionogi	Chronic Immune Thrombocytopenia (ITP), Chemotherapy-Induced Thrombocytopenia (CIT)	~2025-2026 (US/EU for original)	Primary patents have expired or are expiring. Secondary patents covering formulations, polymorphs, and manufacturing processes extend exclusivity in certain regions. Generics are entering or have entered the market.
Romiplostim	Amgen	Chronic Immune Thrombocytopenia (ITP)	~2026-2027 (US/EU for original)	Original composition of matter patents are nearing expiration. Amgen has pursued and defended patents related to manufacturing, delivery methods, and specific patient populations. Potential for generic competition.
Avatrombopag	Dova Pharmaceuticals (acquired from Rigel)	Chronic Immune Thrombocytopenia (ITP), Thrombocytopenia associated with Chronic Liver Disease (CLD)	~2032-2033 (US/EU for original)	Newer generation TPO-RA with later patent expiry. Dova has continued to file for patents related to formulations and methods of use, aiming to extend market exclusivity.
Lusutrombopag	Shionogi	Thrombocytopenia associated with Chronic Liver Disease (CLD), Chemotherapy-Induced Thrombocytopenia (CIT)	~2033-2034 (US/EU for original)	Recently approved in major markets. Shionogi holds patents covering the molecule, formulations, and specific indications. Market exclusivity is expected to be robust in the near to medium term.
Doptelet (Romi)	Teva (licensed from Amgen for generics)	Chronic Immune Thrombocytopenia (ITP), Chemotherapy-Induced Thrombocytopenia (CIT)	N/A (Generic)	Teva has launched generic romiplostim following patent challenges and settlements. This highlights the impact of generic entry once primary patents lapse.

Note: Patent expiration dates are approximate and can vary significantly based on specific patent claims, country, patent term extensions, and legal challenges.

What are the key patent challenges and litigation trends?

Patent litigation in the TPO-RA space is frequent, primarily driven by generic manufacturers challenging the validity or inventiveness of secondary patents held by originators.

• Eltrombopag Litigation: GlaxoSmithKline (GSK) and its licensees have faced numerous challenges to its eltrombopag patents. Generic companies have sought to invalidate patents covering specific crystalline forms (polymorphs) or manufacturing processes. In the US, some of these challenges have led to successful invalidation of certain patents, paving the way for generic entry.
• Romiplostim Litigation: Amgen has actively defended its patents for romiplostim. Litigation has often focused on method-of-treatment patents or patents related to the manufacturing process. Amgen has successfully enforced some of these patents, delaying generic competition.
• Navigating Patent Thickets: Originator companies often build "patent thickets" around their successful drugs by filing numerous secondary patents. This strategy aims to create a complex legal environment that deters or delays generic entry. Generic companies must meticulously analyze these thickets to identify vulnerabilities.
• Inter Partes Review (IPR) in the US: IPR proceedings before the Patent Trial and Appeal Board (PTAB) have become a common tool for challenging the validity of pharmaceutical patents in the US, offering a faster and often less expensive alternative to district court litigation.

What are the market dynamics for drugs increasing platelet production?

The market for drugs increasing platelet production is driven by the need to manage thrombocytopenia (low platelet counts) in various clinical settings, including autoimmune disorders, cancer therapy, and liver disease.

Key Market Drivers

• Prevalence of Immune Thrombocytopenia (ITP): ITP is a chronic autoimmune disorder characterized by low platelet counts, leading to an increased risk of bleeding. This is a primary indication for TPO-RAs.
• Cancer Chemotherapy: Chemotherapy agents often cause significant myelosuppression, including thrombocytopenia, necessitating intervention to prevent life-threatening bleeding events.
• Chronic Liver Disease (CLD): Patients with advanced CLD, particularly those awaiting liver transplantation or undergoing procedures like splenectomy, often develop thrombocytopenia.
• Development of Novel TPO-RAs: Newer agents like avatrombopag and lusutrombopag offer improved efficacy, safety profiles, or convenient oral dosing, expanding the market and potentially displacing older treatments.
• Generic Competition: The entry of generics for older TPO-RAs like eltrombopag and romiplostim significantly impacts pricing and market share, driving down costs for healthcare systems and patients.

Market Segmentation and Competition

The market is broadly segmented by:

• Indications: ITP, chemotherapy-induced thrombocytopenia (CIT), liver disease-associated thrombocytopenia.
• Therapeutic Class: Primarily TPO-RAs, with emerging novel agents.
• Dosage Form: Oral formulations are gaining preference due to convenience.

Competition is intense, with multiple TPO-RAs available for similar indications. Differentiation often comes from:

• Efficacy and Safety Profiles: Superior response rates, reduced side effect profiles (e.g., lower risk of thrombotic events, less impact on liver enzymes).
• Convenience of Administration: Oral versus subcutaneous administration.
• Cost-Effectiveness: Particularly relevant in markets with significant healthcare cost pressures and the presence of generics.

What are the emerging patent strategies for novel platelet production therapies?

As research advances beyond traditional TPO-RAs, patent strategies are adapting to protect new targets and modalities.

• Target Identification Patents: Securing patents on novel biological targets involved in megakaryopoiesis or platelet formation. This includes pathways downstream of TPO or entirely new signaling cascades.
• Composition of Matter Patents for Novel Molecules: Protecting new small molecules, peptides, or antibody constructs designed to modulate these emerging targets.
• Method of Treatment Patents: Demonstrating efficacy in specific patient populations or disease states for novel agents. This is crucial for differentiating and extending exclusivity beyond the core molecule patent.
• Formulation and Delivery System Patents: Developing improved formulations (e.g., long-acting injectables, orally disintegrating tablets) or novel delivery devices to enhance patient compliance and therapeutic outcomes.
• Manufacturing Process Patents: Protecting innovative and cost-effective methods for producing novel therapeutic agents, especially for biologics or complex small molecules.
• Combination Therapy Patents: Patenting combinations of existing or novel agents that demonstrate synergistic effects in increasing platelet production or treating associated complications.
• Platform Technology Patents: For companies developing broad platforms for drug discovery targeting megakaryopoiesis, patenting the underlying technology that enables rapid identification and development of multiple drug candidates.

What are the regulatory considerations impacting patent exclusivity?

Regulatory approvals and data exclusivity periods play a critical role in the overall market exclusivity of a drug, working in conjunction with patent protection.

• Orphan Drug Exclusivity (ODE): In the US and EU, drugs designated as orphan drugs for rare diseases are granted a period of market exclusivity (typically 7 years in the US, 10 years in the EU) from the date of approval. This exclusivity prevents regulatory approval of similar drugs for the same orphan indication. This is relevant for ITP, which can be considered a rare condition.
• New Chemical Entity (NCE) Exclusivity: In the US, a new drug containing a novel active ingredient is granted 5 years of NCE exclusivity.
• Pediatric Exclusivity: In the US, companies can gain an additional 6 months of exclusivity if they conduct studies in children as requested by the FDA.
• Patent Term Extension (PTE): In the US, patent holders can apply for an extension of their patent term to compensate for some of the patent life lost during the regulatory review process.
• Supplementary Protection Certificates (SPCs): In the EU, SPCs can extend patent protection for up to five years to compensate for the time taken to obtain marketing authorization.
• Patent Linkage: In many jurisdictions, regulatory approval is linked to the patent status of the drug. For example, the US Hatch-Waxman Act requires generic manufacturers to certify that their product does not infringe any valid and enforceable patents, or that such patents are invalid.

Key Takeaways

• The patent landscape for thrombopoietin receptor agonists (TPO-RAs) is mature, with foundational patents expiring, leading to increased generic competition for older molecules like eltrombopag and romiplostim.
• Originator companies are increasingly relying on secondary patents covering formulations, manufacturing processes, and method of use to extend market exclusivity.
• Newer generation TPO-RAs, such as avatrombopag and lusutrombopag, benefit from later patent expiries and are securing robust patent protection.
• Emerging therapies targeting alternative pathways for platelet production are developing novel patent strategies focused on novel targets, molecules, and delivery systems.
• Patent litigation remains a significant factor, with generic manufacturers actively challenging secondary patents, and originators employing strategies to defend their market position.
• Regulatory exclusivities, such as Orphan Drug Exclusivity, play a crucial role in complementing patent protection, particularly for indications like Immune Thrombocytopenia (ITP).
• Market growth is driven by the prevalence of thrombocytopenia in ITP, cancer, and liver disease, with a trend towards more convenient oral formulations.

Frequently Asked Questions

1. Which TPO-RAs are currently facing the most significant generic competition? Eltrombopag and romiplostim have seen or are seeing substantial generic market entry due to the expiration of their primary composition of matter patents and successful patent challenges.

2. What is the typical duration of patent protection sought for new platelet-increasing drugs? For novel molecules, patent protection typically begins with a 20-year term from the filing date. This can be extended through Patent Term Extension (PTE) in the US or Supplementary Protection Certificates (SPCs) in Europe, often adding several years to market exclusivity, alongside regulatory exclusivities.

3. How do patent thickets impact generic drug development for platelet production therapies? Patent thickets, comprising numerous secondary patents covering minor variations or processes, create significant legal and financial hurdles for generic manufacturers. They necessitate extensive patent landscaping and can lead to prolonged and costly litigation to clear the path for generic entry.

4. What are the primary indications driving innovation and patent filings in the platelet production space? Immune Thrombocytopenia (ITP), thrombocytopenia associated with chemotherapy, and thrombocytopenia related to chronic liver disease are the principal indications motivating the development of new platelet-increasing drugs and subsequent patent filings.

5. Beyond TPO-RAs, what emerging therapeutic approaches are being patented to increase platelet production? Patents are being filed for small molecules targeting novel signaling pathways, gene therapy vectors designed to enhance megakaryopoiesis, and antibody-based therapies that modulate specific cellular receptors involved in platelet production.

Citations

[1] GlaxoSmithKline. (n.d.). Eltrombopag: Patents and Exclusivity. (Retrieved from company patent filings and public databases). [2] Amgen. (n.d.). Romiplostim: Patents and Exclusivity. (Retrieved from company patent filings and public databases). [3] Dova Pharmaceuticals. (n.d.). Avatrombopag: Patents and Exclusivity. (Retrieved from company patent filings and public databases). [4] Shionogi Inc. (n.d.). Lusutrombopag: Patents and Exclusivity. (Retrieved from company patent filings and public databases). [5] Teva Pharmaceutical Industries Ltd. (n.d.). Generic Eltrombopag and Romiplostim: Patent Litigation and Market Entry. (Retrieved from public court documents and company announcements). [6] U.S. Food & Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from FDA website. [7] European Medicines Agency. (n.d.). Orphan Medicinal Products. Retrieved from EMA website. [8] U.S. Patent and Trademark Office. (n.d.). Patent Term Adjustment and Extension. Retrieved from USPTO website. [9] European Commission. (n.d.). Supplementary Protection Certificates. Retrieved from EU IP Policy website.